Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer
- 14 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Prostate Cancer and Prostatic Diseases
- Vol. 24 (1), 81-87
- https://doi.org/10.1038/s41391-020-0228-0
Abstract
Background Metastatic disease burden out of proportion to serum PSA has been used as a marker of aggressive phenotype prostate cancer but is not well defined as a distinct subgroup. We sought to prospectively characterize the molecular features and clinical outcomes of Low PSA Secretors. Methods Eligible metastatic castration resistant prostate cancer (mCRPC) patients without prior small cell histology underwent metastatic tumor biopsy with molecular characterization. Low PSA secretion was defined as serum PSA < 2, 5, or 10 ng/mL plus >5 metastases with radiographic progression at study entry. Clinical and molecular features were compared between low PSA vs. normal secretors in a post-hoc fashion. Results 183 patients were enrolled, including 15 (8%) identified as Low PSA Secretors using optimal PSA cut point of 5 ng/mL. Biopsies from Low PSA Secretors demonstrated higher t-SCNC and RB1 loss and lower AR transcriptional signature scores compared with normal secretors. Genomic loss of RB1 and/or TP53 was more common in Low PSA Secretors (80% vs. 41%). Overall survival (OS) was shorter in Low PSA Secretors (median OS = 26.7 vs. 46.0 months, hazard ratio = 2.465 (95% CI: 0.982–6.183). Progression-free survival (PFS) on post-biopsy treatment with AR-targeted therapy was shorter than with chemotherapy (median PFS 6.2 vs. 4.1 months). Conclusions Low PSA secretion in relation to metastatic tumor burden may be a readily available clinical selection tool for de-differentiated mCRPC with molecular features consistent with t-SCNC. Prospective validation is warranted.Keywords
This publication has 24 references indexed in Scilit:
- Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate CancersClinical Cancer Research, 2016
- Divergent clonal evolution of castration-resistant neuroendocrine prostate cancerNature Medicine, 2016
- Development and Validation of a Scalable Next-Generation Sequencing System for Assessing Relevant Somatic Variants in Solid TumorsNeoplasia, 2015
- Enzalutamide in Metastatic Prostate Cancer before ChemotherapyThe New England Journal of Medicine, 2014
- Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine DifferentiationThe American Journal of Surgical Pathology, 2014
- Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate CancerClinical Cancer Research, 2013
- Abiraterone in Metastatic Prostate Cancer without Previous ChemotherapyThe New England Journal of Medicine, 2013
- Understanding the Lethal Variant of Prostate Cancer: Power of Examining ExtremesCancer Discovery, 2011
- Small Cell Carcinoma of the ProstateThe American Journal of Surgical Pathology, 2008
- Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cellsEndocrine-Related Cancer, 2007